Trials / Completed
CompletedNCT03538041
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of parsaclisib administered orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin and evidence of ongoing hemolysis that requires treatment intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Parsaclisib | Parsaclisib administered orally. |
Timeline
- Start date
- 2018-11-21
- Primary completion
- 2021-08-05
- Completion
- 2024-04-02
- First posted
- 2018-05-25
- Last updated
- 2025-07-11
- Results posted
- 2022-09-22
Locations
12 sites across 4 countries: United States, Austria, France, Italy
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03538041. Inclusion in this directory is not an endorsement.